Matinas BioPharma (MTNB) News Today $0.17 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period June 24, 2024 | globenewswire.comMatinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramJune 13, 2024 | globenewswire.comMatinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.May 16, 2024 | investorplace.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 16, 2024 | finance.yahoo.comNew In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | globenewswire.comNew In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal CandidateMay 10, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Matinas BioPharma Holdings Inc Earnings CallMay 10, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 9, 2024 | investorplace.comMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024May 9, 2024 | globenewswire.comMatinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 7, 2024 | finance.yahoo.comMatinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingMay 2, 2024 | globenewswire.comMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024April 30, 2024 | msn.comOral fungal infection treatment shows promise in preclinical trialsApril 30, 2024 | finance.yahoo.comIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyApril 3, 2024 | msn.comMatinas Declines on Public OfferingApril 3, 2024 | globenewswire.comMatinas BioPharma Prices $10 Million Registered Direct OfferingApril 1, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 28, 2024 | marketbeat.comMatinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings ResultsMatinas BioPharma (NYSEAMERICAN:MTNB - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter.March 28, 2024 | finance.yahoo.comQ4 2023 Matinas BioPharma Holdings Inc Earnings CallMarch 27, 2024 | investorplace.comMTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023March 27, 2024 | globenewswire.comMatinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 25, 2024 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 25, 2024 | globenewswire.comMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 22, 2024 | finance.yahoo.comWhy Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?March 22, 2024 | finance.yahoo.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.comMatinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsMarch 12, 2024 | marketbeat.comMatinas BioPharma (MTNB) to Release Quarterly Earnings on WednesdayMatinas BioPharma (NYSEAMERICAN:MTNB) will be releasing earnings on Wednesday, March 13, Yahoo Finance reports.March 3, 2024 | uk.finance.yahoo.comMatinas BioPharma Holdings, Inc. (MTNB)February 28, 2024 | wsj.comMatinas BioPharma Holdings Inc.February 26, 2024 | finance.yahoo.comMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionFebruary 23, 2024 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 20, 2024 | globenewswire.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 4, 2024 | seekingalpha.comAVBP ArriVent BioPharma, Inc.January 21, 2024 | morningstar.comMatinas BioPharma Holdings Inc MTNBJanuary 3, 2024 | finance.yahoo.comMatinas BioPharma to Present at Biotech Showcase 2024December 27, 2023 | finance.yahoo.comMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesDecember 21, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDADecember 21, 2023 | markets.businessinsider.comMatinas BioPharma Plans To Meet With FDA In Q1 To Finalize Phase 3 Protocol For MAT2203December 21, 2023 | finance.yahoo.comMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDADecember 20, 2023 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB), Guidance and ForecastNovember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Shattuck Labs (STTK) and Matinas BioPharma (MTNB)November 10, 2023 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Matinas BioPharma Holdings Inc Earnings CallNovember 8, 2023 | finance.yahoo.comMatinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business ProgressNovember 8, 2023 | finance.yahoo.comMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update Get Matinas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia’s Quiet $1 Trillion Pivot (Ad)Nvidia recently added $277 billion in market cap … IN ONE DAY. Find out details on these three critical Nvidia partners immediately. MTNB Media Mentions By Week MTNB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTNB News Sentiment▼1.000.62▲Average Medical News Sentiment MTNB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTNB Articles This Week▼11▲MTNB Articles Average Week Get Matinas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMMP News RPTX News KOD News ADVM News GALT News SYRS News CGEN News PRQR News CYDY News IXHL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:MTNB) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.